Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Buy" from Brokerages

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been given an average recommendation of "Buy" by the seven research firms that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $11.00.

A number of research analysts have commented on ACRS shares. BTIG Research raised Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $8.00 price target for the company in a research report on Tuesday, November 19th. Leerink Partners upgraded Aclaris Therapeutics from a "market perform" rating to an "outperform" rating and upped their target price for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. HC Wainwright upgraded shares of Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $20.00 price target on the stock in a report on Monday, December 23rd. Jefferies Financial Group raised shares of Aclaris Therapeutics from a "hold" rating to a "buy" rating and boosted their price objective for the company from $2.00 to $7.00 in a research report on Tuesday, November 19th. Finally, Leerink Partnrs raised shares of Aclaris Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, November 19th.

Institutional Trading of Aclaris Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Jefferies Financial Group Inc. increased its position in Aclaris Therapeutics by 253.9% during the 4th quarter. Jefferies Financial Group Inc. now owns 40,700 shares of the biotechnology company's stock valued at $101,000 after buying an additional 29,200 shares in the last quarter. Alpine Global Management LLC bought a new position in shares of Aclaris Therapeutics during the fourth quarter valued at $38,000. Velan Capital Investment Management LP purchased a new position in shares of Aclaris Therapeutics in the 4th quarter worth about $67,000. Squarepoint Ops LLC raised its position in shares of Aclaris Therapeutics by 108.3% in the 4th quarter. Squarepoint Ops LLC now owns 292,892 shares of the biotechnology company's stock worth $726,000 after purchasing an additional 152,312 shares during the last quarter. Finally, Man Group plc bought a new position in Aclaris Therapeutics in the 4th quarter worth about $133,000. 98.34% of the stock is owned by institutional investors.

Remove Ads

Aclaris Therapeutics Stock Up 0.5 %

Shares of NASDAQ:ACRS traded up $0.01 during midday trading on Tuesday, hitting $1.83. 1,197,738 shares of the stock traded hands, compared to its average volume of 768,692. The business's 50 day moving average is $2.36 and its two-hundred day moving average is $2.17. The stock has a market capitalization of $130.72 million, a PE ratio of -3.52 and a beta of 0.50. Aclaris Therapeutics has a one year low of $0.95 and a one year high of $5.17.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.